Polyneuropathy Clinical Trials

54 recruitingLast updated: May 13, 2026

There are 54 actively recruiting polyneuropathy clinical trials across 52 countries. Studies span Not Applicable, Phase 3, Phase 2, Phase 1, Phase 4, Early Phase 1. Top locations include Philadelphia, Pennsylvania, United States, Copenhagen, Denmark, Pavia, Italy. Updated daily from ClinicalTrials.gov.


Polyneuropathy Trials at a Glance

54 actively recruiting trials for polyneuropathy are listed on ClinicalTrialsFinder across 6 cities in 52 countries. The largest study group is Not Applicable with 12 trials, with the heaviest enrollment activity in Philadelphia, Copenhagen, and Pavia. Lead sponsors running polyneuropathy studies include Sanofi, argenx, and CSL Behring.

Browse polyneuropathy trials by phase

Treatments under study

About Polyneuropathy Clinical Trials

Looking for clinical trials for Polyneuropathy? There are currently 4 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Polyneuropathy trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Polyneuropathy clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 54 trials

Recruiting
Phase 3

A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP

Chronic Inflammatory Demyelinating PolyneuropathyChronic Inflammatory Demyelinating PolyradiculoneuropathyCIDP
argenx160 enrolled43 locationsNCT07091630
Recruiting
Early Phase 1

CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases

Relapsing or Refractory Multiple Sclerosis (MS)Myasthenia Gravis (MG)Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)+1 more
Tongji Hospital36 enrolled1 locationNCT07337785
Recruiting
Phase 1

Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.

Neuromyelitis Optica Spectrum Disorder (NMOSD)Multiple Sclerosis (MS)Myasthenia Gravis (MG)+4 more
Tongji Hospital6 enrolled1 locationNCT07526493
Recruiting
Phase 3

A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP

Chronic Inflammatory Demyelinating PolyneuropathyCIDPCIDP - Chronic Inflammatory Demyelinating Polyneuropathy
argenx218 enrolled73 locationsNCT06920004
Recruiting
Phase 3

A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Chronic Inflammatory Demyelinating Polyneuropathy
Sanofi160 enrolled118 locationsNCT06290141
Recruiting
Phase 3

A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work

Chronic Inflammatory Demyelinating PolyradiculoneuropathyPolyneuropathy, Inflammatory Demyelinating, Chronic
Sanofi140 enrolled125 locationsNCT06290128
Recruiting
Phase 2

Zanubritnib and Anti-MAG Neuropathy

Anti-MAG IgM-associated Demyelinating Polyneuropathy
Azienda Ospedaliera di Padova50 enrolled1 locationNCT07392229
Recruiting

Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program

PolyneuropathyHereditary Transthyretin-mediated (hATTR) Amyloidosis
Alnylam Pharmaceuticals10 enrolled7 locationsNCT05040373
Recruiting
Phase 2

IMVT-1402 in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Chronic Inflammatory Demyelinating Polyneuropathy
Immunovant Sciences GmbH162 enrolled135 locationsNCT07032662
Recruiting
Phase 1

A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases

Myasthenia GravisMultiple SclerosisChronic Inflammatory Demyelinating Polyneuropathy
Kite, A Gilead Company52 enrolled3 locationsNCT07304154
Recruiting
Phase 3

TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy

Hereditary Transthyretin-Mediated Amyloidosis With PolyneuropathyhATTR-PN
Alnylam Pharmaceuticals125 enrolled4 locationsNCT07223203
Recruiting
Phase 3

A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)

Chronic Inflammatory Demyelinating Polyneuropathy
Dianthus Therapeutics256 enrolled158 locationsNCT06858579
Recruiting
Phase 3

A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Chronic Inflammatory Demyelinating Polyneuropathy
Kedrion S.p.A.161 enrolled2 locationsNCT06752356
Recruiting
Phase 2

Peripheral Magnetic Stimulation With Balance Training to Decrease Fall Risks in Diabetic Polyneuropathy

Diabetic Polyneuropathy
Queen Savang Vadhana Memorial Hospital, Thailand40 enrolled1 locationNCT07000214
Recruiting

Critical Illness Weakness Outside the Intensive Care Unit.

Critical Illness MyopathyCritical Illness PolyneuropathyCritical Illness Polyneuromyopathy
Istituto Clinico Humanitas300 enrolled1 locationNCT07478367
Recruiting
Not Applicable

Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease

Myasthenia GravisAmyotrophic Lateral SclerosisNeuromuscular Diseases (NMD)+15 more
University of Missouri-Columbia50 enrolled1 locationNCT07478172
Recruiting

Subcutaneous Immunoglobulin Therapy Effectiveness Monitoring in CIDP Patients Using Smart Devices

CIDP - Chronic Inflammatory Demyelinating Polyneuropathy
Heinrich-Heine University, Duesseldorf35 enrolled2 locationsNCT07273903
Recruiting

Studying Nerve Function and Structure in Charcot-Marie-Tooth Disease, Anti-MAG Neuropathy and CIDP

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Charcot-Marie-ToothCMT1A+2 more
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta39 enrolled1 locationNCT07461896
Recruiting

Metabolomics Study on Postoperative Intensive Care Acquired Muscle Weakness

Muscle WeaknessMetabolomicsCritical Illness+4 more
Technical University of Munich20 enrolled3 locationsNCT03810768
Recruiting
Not Applicable

FOot CAre and Exercises ImplementatioN for People With Diabetes in Primary Care

Diabetes; Neuropathy, Polyneuropathy (Manifestation)
University of Sao Paulo General Hospital356 enrolled1 locationNCT05639478